BeOne Medicines (ONC) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $374.08, +6.43% vs the prior close of $351.48.
- Volume 744.80K shares, 1.9x its 50-day average (heavy).
- New SEC filings: 4 (Oct 15, 2026).
- No new insider buys or sales reported since the prior session.
ONC jumps 6.4% to $374.08, a 1-month high on 1.9x normal volume. Closed at $374.08, +6.43% vs the prior close of $351.48. Day range $355.24–$375.64, opened at $356.61.
ONC daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — ONC jumps 6.4% to $374.08, a 1-month high on 1.9x normal volume
- Closed at $374.08, +6.43% vs the prior close of $351.48. Day range $355.24–$375.64, opened at $356.61.
- Volume was 744.80K shares, 1.9x its 50-day average of 386.33K — unusually heavy trading.
- Price is +4.1% vs its 50-day average ($359.43) and +16.1% vs its 200-day average ($322.22).
- 52-week range $253.95–$385.22; today's close sits at 92% of that range, 2.9% below the 52-week high.
Oct 14, 2026 — ONC rises 0.7% to $351.48
- Closed at $351.48, +0.69% vs the prior close of $349.08. Day range $344.94–$355.76, opened at $346.05.
- Volume was 361.60K shares, 0.9x its 50-day average of 386.81K.
- Price is -2.0% vs its 50-day average ($358.50) and +9.2% vs its 200-day average ($321.90).
- 52-week range $253.95–$385.22; today's close sits at 74% of that range, 8.8% below the 52-week high.
Oct 13, 2026 — ONC dips 0.4% to $349.08
- Closed at $349.08, -0.38% vs the prior close of $350.40. Day range $348.73–$354.67, opened at $354.33.
- Volume was 287.40K shares, 0.7x its 50-day average of 388.25K.
- Price is -2.5% vs its 50-day average ($357.93) and +8.5% vs its 200-day average ($321.70).
- 52-week range $253.95–$385.22; today's close sits at 72% of that range, 9.4% below the 52-week high.
Oct 12, 2026 — ONC dips 1.1% to $350.40
- Closed at $350.40, -1.15% vs the prior close of $354.47. Day range $346.61–$354.15, opened at $352.55.
- Volume was 259.30K shares, 0.7x its 50-day average of 388.06K.
- Price is -1.9% vs its 50-day average ($357.22) and +9.0% vs its 200-day average ($321.52).
- 52-week range $253.95–$385.22; today's close sits at 73% of that range, 9.0% below the 52-week high.
Oct 9, 2026 — ONC rises 1.2% to $354.47
- Closed at $354.47, +1.24% vs the prior close of $350.13. Day range $347.72–$357.14, opened at $348.00.
- Volume was 318.30K shares, 0.8x its 50-day average of 385.98K.
- Price is -0.6% vs its 50-day average ($356.54) and +10.3% vs its 200-day average ($321.33).
- 52-week range $253.95–$385.22; today's close sits at 77% of that range, 8.0% below the 52-week high.
Oct 8, 2026 — ONC slides 3.8% to $350.13
- Closed at $350.13, -3.82% vs the prior close of $364.02. Day range $340.45–$355.01, opened at $351.94.
- Volume was 418.70K shares, 1.1x its 50-day average of 381.39K.
- Price is -1.6% vs its 50-day average ($355.89) and +9.0% vs its 200-day average ($321.12).
- 52-week range $253.95–$385.22; today's close sits at 73% of that range, 9.1% below the 52-week high.
Oct 7, 2026 — ONC rises 0.3% to $364.02, 3 up days in a row
- Closed at $364.02, +0.34% vs the prior close of $362.78. Day range $359.41–$367.57, opened at $360.01.
- Volume was 148.60K shares, 0.4x its 50-day average of 383.57K — lighter than usual.
- Price is +2.4% vs its 50-day average ($355.43) and +13.4% vs its 200-day average ($320.95).
- 52-week range $253.95–$385.22; today's close sits at 84% of that range, 5.5% below the 52-week high.
- That makes 3 straight gains.
Oct 6, 2026 — ONC rises 0.3% to $362.78
- Closed at $362.78, +0.31% vs the prior close of $361.65. Day range $359.10–$368.40, opened at $365.13.
- Volume was 319.90K shares, 0.8x its 50-day average of 383.22K.
- Price is +2.3% vs its 50-day average ($354.76) and +13.1% vs its 200-day average ($320.67).
- 52-week range $253.95–$385.22; today's close sits at 83% of that range, 5.8% below the 52-week high.
Oct 5, 2026 — ONC rises 1.0% to $361.65
- Closed at $361.65, +1.00% vs the prior close of $358.07. Day range $356.82–$362.83, opened at $362.48.
- Volume was 392.10K shares, 1.0x its 50-day average of 382.34K.
- Price is +2.2% vs its 50-day average ($354.02) and +12.9% vs its 200-day average ($320.38).
- 52-week range $253.95–$385.22; today's close sits at 82% of that range, 6.1% below the 52-week high.
Oct 2, 2026 — ONC ends flat (-0.2%) to $358.07
- Closed at $358.07, -0.20% vs the prior close of $358.77. Day range $349.74–$358.57, opened at $351.01.
- Volume was 505.20K shares, 1.3x its 50-day average of 383.17K.
- Price is +1.3% vs its 50-day average ($353.31) and +11.9% vs its 200-day average ($320.10).
- 52-week range $253.95–$385.22; today's close sits at 79% of that range, 7.0% below the 52-week high.
ONC latest news & SEC filings
Every SEC filing by or about ONC in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 15, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Wang Xiaodong converted options/RSUs into 31,027 shares at $36.90 (≈$1.14M) on Oct 13, 2026; now holds 31,027
- Wang Xiaodong sold 7,167 shares at $349.56 (≈$2.51M) on Oct 13, 2026; now holds 23,860
- Wang Xiaodong sold 10,361 shares at $350.47 (≈$3.63M) on Oct 13, 2026; now holds 13,499
- Wang Xiaodong sold 5,681 shares at $351.40 (≈$2.00M) on Oct 13, 2026; now holds 7,818
- Wang Xiaodong sold 6,558 shares at $352.57 (≈$2.31M) on Oct 13, 2026; now holds 1,260
- Wang Xiaodong sold 1,260 shares at $353.24 (≈$445.08K) on Oct 13, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Lee Chan Henry sold 1,115 shares at $375.00 (≈$418.12K) on Sep 30, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 30, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Wang Xiaodong converted options/RSUs into 31,028 shares at $36.90 (≈$1.14M) on Sep 28, 2026; now holds 31,028
- Wang Xiaodong sold 160 shares at $356.97 (≈$57.11K) on Sep 28, 2026; now holds 30,868
- Wang Xiaodong sold 120 shares at $358.71 (≈$43.04K) on Sep 28, 2026; now holds 30,748
- Wang Xiaodong sold 40 shares at $359.16 (≈$14.37K) on Sep 28, 2026; now holds 30,708
- Wang Xiaodong sold 2,241 shares at $361.05 (≈$809.12K) on Sep 28, 2026; now holds 28,467
- Wang Xiaodong sold 4,239 shares at $362.17 (≈$1.54M) on Sep 28, 2026; now holds 24,228
- …plus 5 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 30, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 16, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 16, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Baker Bros. Advisors Lp & 667, L.P. & Baker Bros. Advisors (Gp) Llc & Baker Brothers Life Sciences Lp & Baker Felix & Baker Julian converted options/RSUs into 30,768 shares at $36.83 (≈$1.13M) on Sep 14, 2026; now holds 761,410
- Baker Bros. Advisors Lp & 667, L.P. & Baker Bros. Advisors (Gp) Llc & Baker Brothers Life Sciences Lp & Baker Felix & Baker Julian converted options/RSUs into 30,768 shares at $36.83 (≈$1.13M) on Sep 14, 2026; now holds 8,099,179
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Wang Xiaodong sold 10,688 shares at $349.28 (≈$3.73M) on Sep 8, 2026
- Wang Xiaodong sold 7,492 shares at $348.31 (≈$2.61M) on Sep 8, 2026
- Wang Xiaodong sold 1,181 shares at $345.38 (≈$407.89K) on Sep 8, 2026
- Wang Xiaodong sold 6,569 shares at $350.27 (≈$2.30M) on Sep 8, 2026
- Wang Xiaodong sold 1,721 shares at $348.01 (≈$598.93K) on Sep 8, 2026
- Wang Xiaodong sold 1,517 shares at $347.39 (≈$526.99K) on Sep 8, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 26, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $1.71B (prior year $1.32B) (+29.6% vs Jun 30, 2025)
- Net income: $237.01M (prior year $94.32M) (+151.3% vs Jun 30, 2025)
- Diluted EPS: $0.16 (prior year $0.06) (+166.7% vs Jun 30, 2025)
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jun 26, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade ONC
- Last results release: Aug 26, 2026 (8-K Item 2.02). Previous ones: Aug 5, 2026, May 6, 2026, Apr 14, 2026. Based on that rhythm, the next report is likely around Nov 25, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.40% (largest 6.4%).
- Liquidity: about 391.56K shares (≈$146.47M) trade per day on average.
- 52-week position: $374.08 vs a range of $253.95–$385.22 (92% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Xiaodong Wang sold 160 shares on Sep 28, 2026.
- Latest filings: 8-K Aug 26, 2026; 10-Q Aug 5, 2026; 8-K Aug 5, 2026.
- Share count: 1.48B shares outstanding (Jul 31, 2026), +3.3% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ONC market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 356.61 | 375.64 | 355.24 | 374.08 | 744.80K |
| Oct 14, 2026 | 346.05 | 355.76 | 344.94 | 351.48 | 361.60K |
| Oct 13, 2026 | 354.33 | 354.67 | 348.73 | 349.08 | 287.40K |
| Oct 12, 2026 | 352.55 | 354.15 | 346.61 | 350.40 | 259.30K |
| Oct 9, 2026 | 348.00 | 357.14 | 347.72 | 354.47 | 318.30K |
| Oct 8, 2026 | 351.94 | 355.01 | 340.45 | 350.13 | 418.70K |
| Oct 7, 2026 | 360.01 | 367.57 | 359.41 | 364.02 | 148.60K |
| Oct 6, 2026 | 365.13 | 368.40 | 359.10 | 362.78 | 319.90K |
| Oct 5, 2026 | 362.48 | 362.83 | 356.82 | 361.65 | 392.10K |
| Oct 2, 2026 | 351.01 | 358.57 | 349.74 | 358.07 | 505.20K |
| Oct 1, 2026 | 367.94 | 371.09 | 358.32 | 358.77 | 351.40K |
| Sep 30, 2026 | 370.00 | 376.50 | 365.79 | 365.94 | 328.90K |
| Sep 29, 2026 | 362.76 | 367.43 | 357.17 | 365.27 | 372.80K |
| Sep 28, 2026 | 360.42 | 368.05 | 358.00 | 367.00 | 350.50K |
| Sep 25, 2026 | 362.51 | 365.00 | 358.51 | 360.85 | 377.20K |
| Sep 24, 2026 | 355.37 | 361.12 | 354.94 | 359.97 | 472.80K |
| Sep 23, 2026 | 362.50 | 365.70 | 361.31 | 365.00 | 631.80K |
| Sep 22, 2026 | 364.95 | 368.28 | 359.82 | 368.08 | 262.90K |
| Sep 21, 2026 | 360.42 | 367.00 | 358.24 | 365.67 | 488.60K |
| Sep 18, 2026 | 352.13 | 354.05 | 348.76 | 350.84 | 438.40K |
About BeOne Medicines
BeOne Medicines (ONC) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in BASEL. Fiscal year ends December 31. SEC CIK 1651308.
ONC board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| L.P. 667, | Director | Sep 16, 2026 |
| Bros. Advisors Lp Baker | Director | Sep 16, 2026 |
| Felix Baker | Director | Sep 16, 2026 |
| Julian Baker | Director | Sep 16, 2026 |
| Olivier Brandicourt | Director | Jun 15, 2026 |
| Bros. Advisors (Gp) Llc Baker | Director | Sep 16, 2026 |
| Brothers Life Sciences Lp Baker | Director | Sep 16, 2026 |
| Margaret Dugan | Director | Jun 15, 2026 |
| Anthony C Hooper | Director | Jun 15, 2026 |
| Elizabeth Fisher Mooney | Director | Jun 15, 2026 |
| John Oyler | Chief Executive Officer | Aug 12, 2026 |
| Alessandro Riva | Director | Jun 15, 2026 |
| Corazon (Corsee) D. Sanders | Director | May 27, 2026 |
| Charles Lazelle Sawyers | Director | Jun 15, 2026 |
| Shalini Sharp | Director | Jun 15, 2026 |
| Xiaodong Wang | Chair, Scientific Advisory Brd | Sep 30, 2026 |
| Qingqing Yi | Director | Jun 3, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Titus B. Ball | Principal Accounting Officer | Sep 3, 2026 |
| Chan Henry Lee | SVP, General Counsel | Aug 13, 2026 |
| John Oyler | Chief Executive Officer | Aug 12, 2026 |
| Aaron Rosenberg | Chief Financial Officer | Aug 5, 2026 |
| Lai Wang | President, Global Head of R&D | Jun 25, 2026 |
| Xiaobin Wu | President and COO | Aug 27, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 28, 2026 | Xiaodong Wang | Sale | 160 | $356.97 |
| Sep 28, 2026 | Xiaodong Wang | Sale | 120 | $358.71 |
| Sep 28, 2026 | Xiaodong Wang | Sale | 40 | $359.16 |
| Sep 28, 2026 | Xiaodong Wang | Sale | 2,241 | $361.05 |
| Sep 28, 2026 | Xiaodong Wang | Sale | 738 | $367.23 |
| Sep 28, 2026 | Xiaodong Wang | Sale | 3,499 | $363.10 |
| Sep 28, 2026 | Xiaodong Wang | Sale | 3,419 | $364.07 |
| Sep 28, 2026 | Xiaodong Wang | Sale | 2,047 | $365.85 |
| Sep 28, 2026 | Xiaodong Wang | Sale | 14,525 | $366.58 |
| Sep 28, 2026 | Xiaodong Wang | Sale | 4,239 | $362.17 |
| Sep 8, 2026 | Xiaodong Wang | Sale | 10,688 | $349.28 |
| Sep 8, 2026 | Xiaodong Wang | Sale | 7,492 | $348.31 |
| Sep 8, 2026 | Xiaodong Wang | Sale | 1,181 | $345.38 |
| Sep 8, 2026 | Xiaodong Wang | Sale | 6,569 | $350.27 |
| Sep 8, 2026 | Xiaodong Wang | Sale | 1,721 | $348.01 |
ONC financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $5.34B | $286.93M | 0.19 | $1.13B |
| Dec 31, 2024 | $3.81B | $-644.79M | -0.47 | $-140.63M |
| Dec 31, 2023 | $2.46B | $-881.71M | -0.65 | $-1.16B |
| Dec 31, 2022 | $1.42B | $-2.00B | -1.49 | $-1.50B |
| Dec 31, 2021 | $1.18B | $-1.46B | -1.21 | $-1.30B |
Latest balance sheet: total assets $9.18B, total liabilities $4.00B, cash $5.10B (as of Jun 30, 2026).
ONC earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 26, 2026 | 8-K Item 2.02 (results) | $375.80 |
| Aug 5, 2026 | 8-K Item 2.02 (results) | $327.53 |
| May 6, 2026 | 8-K Item 2.02 (results) | $313.32 |
| Apr 14, 2026 | 8-K Item 2.02 (results) | $310.00 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $322.37 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $332.36 |
| Aug 29, 2025 | 8-K Item 2.02 (results) | $306.05 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $298.52 |
| May 7, 2025 | 8-K Item 2.02 (results) | $232.25 |
| Apr 28, 2025 | 8-K Item 2.02 (results) | $249.46 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $278.38 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $193.64 |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on ONC
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.